Cite
HARVARD Citation
Saddi, J. et al. (n.d.). 198TiP DEDALUS trial: A single-arm, phase II, multi-center study of chemo-immunotherapy followed by hypo-fractionated RT and maintenance immunotherapy in patients with unresectable stage III NSCLC. Immuno-oncology technology. p. . [Online].